Stocks and Investing Stocks and Investing
Wed, July 7, 2021
Tue, July 6, 2021
Mon, July 5, 2021
Fri, July 2, 2021
Thu, July 1, 2021
Wed, June 30, 2021
Tue, June 29, 2021
Mon, June 28, 2021

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $140 on, Jun 28th, 2021


Published on 2024-10-27 17:04:23 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $176 to $140 on, Jun 28th, 2021.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Raghuram


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $125 on, Wednesday, June 23rd, 2021
  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021